FDC
Drug Manufacturers - Specialty & Generic · FDC
Mid CapHealthcareMature Stable
Mohan A. Chandavarkar
Managing Director · Pragmatic
Company DNA
Hierarchical
About
FDC is a Mid Cap company in the Healthcare sector, listed on NSE as FDC. With a market cap of ₹6K Cr and revenue of ₹2K Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Traditionalist approach to innovation, the company operates at a Steady-Marathon pace. Long-standing family-led pharmaceutical firm with conservative management style and strong adherence to traditional corporate structures. Its strategic mandate: Needs to move beyond legacy product dependence by investing in R&D and niche therapeutic segment expansion.
FAQ
What kind of company is FDC?
FDC is a Mid Cap Healthcare company (FDC) in the Mature Stable phase with a market cap of ₹6K Cr. It is classified as Hierarchical in culture.
What is FDC's culture and work environment like?
FDC has a Hierarchical culture with Traditionalist innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: Mass-Consumer. Long-standing family-led pharmaceutical firm with conservative management style and strong adherence to traditional corporate structures.
Who leads FDC?
FDC is led by Mohan A. Chandavarkar (Managing Director), a Pragmatic leader with 63 years of experience.
What are FDC's financials?
FDC reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of 11.4%. Operating margin: 12.9%. Market cap: ₹6K Cr.
Culture & Strategy
CultureHierarchical
InnovationTraditionalist
PaceSteady-Marathon
PurposeProfit-Pure
CustomerMass-Consumer
EmployeeSteady Employer
BrandTrusted
LifecycleMature Stable
Long-standing family-led pharmaceutical firm with conservative management style and strong adherence to traditional corporate structures.
Mandate
Needs to move beyond legacy product dependence by investing in R&D and niche therapeutic segment expansion.
Needs to move beyond legacy product dependence by investing in R&D and niche therapeutic segment expansion.
Financials
Revenue FY25₹2K Cr
PAT FY25₹267 Cr
Rev CAGR 5Y11.4%
OPM12.9%
NPM12.7%
ROE11.7%
ROCE11.5%
P/E26.5
Fwd P/E15.1
P/B2.4
D/E0.9
Mkt Cap₹6K Cr
Promoter70%
Institutional7.5%
Similar Culture
Could You Lead FDC?
Take the Genome Benchmark →